Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 9,719 shares at $130.58 ($1.3M) on 2018-12-10, disclosed to the SEC on 2018-12-12.
Open-market sale of $1.3M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.58 | 969 | $127K | 9.6% |
| 2 | $132.09 | 2,001 | $264K | 20.1% |
| 3 | $134.31 | 2,049 | $275K | 21.0% |
| 4 | $136.48 | 400 | $55K | 4.2% |
| 5 | $137.39 | 100 | $14K | 1.0% |
| 6 | $134.63 | 647 |
| $87K |
| 6.6% |
| 7 | $135.76 | 1,153 | $157K | 11.9% |
| 8 | $139.05 | 1,100 | $153K | 11.6% |
| 9 | $140.15 | 1,200 | $168K | 12.8% |
| 10 | $140.61 | 100 | $14K | 1.1% |
| Total | $135.12 avg | 9,719 | $1.3M | 100% |
| Filing → |
| LOXO | SELL | 2018-10-05 | $5.4M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $5.0M | — | Filing → |
| LOXO | SELL | 2018-08-15 | $4.6M | — | Filing → |